Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
521 articles by Ben Fidler
-
With new startup Bitterroot, Forty Seven founder takes aim at heart disease
June 7, 2023 -
Using twin viruses, startup AAVantgarde aims to extend gene therapy’s reach
June 6, 2023 -
Antibiotic maker Paratek, low on cash, agrees to a buyout
June 6, 2023 -
An unconventional drug startup lures Vertex founder Josh Boger back to biotech
June 5, 2023 -
FDA clears narrow use of Lynparza in early prostate cancer, continuing ‘shift’ on PARP drugs
June 1, 2023 -
Sanofi drug, acquired from a startup, shows early potential in MS
May 31, 2023 -
Rain Oncology to cut workforce by 65% after study failure
May 30, 2023 -
Akebia says FDA will give its once-rejected anemia pill a second chance
May 30, 2023 -
Annexon claims a silver lining in failed eye drug study
May 25, 2023 -
FDA delays decision on Duchenne gene therapy, considers narrower approval
May 24, 2023 -
Blueprint wins key FDA approval for rare disease drug
May 23, 2023 -
Future of Intercept’s NASH drug in doubt after FDA panel rejection
May 21, 2023 -
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
May 17, 2023 -
Roche pushes forward with MS drug amid rivals’ setbacks
May 17, 2023 -
FDA panel narrowly backs approval of Sarepta’s Duchenne gene therapy
May 12, 2023 -
FDA staff skeptical of Sarepta’s Duchenne gene therapy, documents show
May 10, 2023 -
‘The luckiest of the unlucky’: A Duchenne gene therapy brings hope to families — and tests the FDA
May 7, 2023 -
Astellas to acquire eye drug developer Iveric Bio for $5.9B
May 1, 2023 -
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
April 16, 2023 -
GSK outlines deal to send cell therapies back to Adaptimmune
April 11, 2023 -
Biotech fears ‘dangerous’ precedent as judge challenges FDA authority
April 10, 2023 -
Merck, Eisai report pair of study setbacks for cancer drug combo
April 7, 2023 -
5 FDA decisions to watch in the second quarter
April 3, 2023 -
Gene therapy startup Vedere to close two years after launch
April 2, 2023 -
Regeneron bets on ‘Treg’ cell therapy with Sonoma deal
March 28, 2023